Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

State of the Art in the Diagnosis and Treatment of Mood Disorders

Premiere Date: Monday, May 8, 2017

This activity offers CE credit for:

1. Physicians (CME)
2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, May 8, 2018
Note: Credit Is No Longer Available

Faculty

Joseph R. Calabrese, MD  Bipolar Disorders Research Chair and Professor of Psychiatry Case Western Reserve University School of Medicine Director, Mood Disorders Program University Hospitals Case Medical Center Cleveland, OH

Charles B. Nemeroff, MD, PhD  Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX

Statement of Need

Bipolar disorder is a frequent and clinically complex psychiatric disorder. Patients with bipolar disorder are exceptionally challenging to manage because of the dynamic, chronic, and fluctuating nature of their disease. These patients frequently have co-occurring disorders that can impact treatment selection. While healthcare providers may see mixed features in depressed and bipolar depressed patients in daily practice, they may not appreciate that the presence of mixed states is a particular danger to patients.

In this CME Outfitters Snack, expert faculty will discuss changes to the DSM-5 for patients with mood disorders, selecting appropriate treatment, the importance of a collaborative interview and the impact of co-occurring disorders.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Integrate recent changes in DSM-5 into your individualized care for patients with mood disorders.
• Recognize the high incidence of depressive symptoms in patients with bipolar disorder and target treatments appropriately.
• Include families and significant others into the assessment of patients with bipolar disorder.

Financial Support

Supported by CME Outfitters, LLC.

Target Audience

Physicians and other healthcare professionals treating patients with mood disorders.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit^TM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)^TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit^TM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST21248 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Calabrese has no disclosures to report.

Dr. Nemeroff has disclosed that he receives grants/research support from National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Fortress Biotech; Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); Xhale, Inc. He is a stockholder of AbbVie Inc.; Bracket; Celgene Corporation; Intermediate Holding Corp.; Network Life Sciences Inc.; OPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; Xhale, Inc. He has patents for Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). He serves on the scientific advisory boards of American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara); Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Laureate Institute for Brain Research, Inc. RiverMend Health, LLC; Skyland Trail; Xhale, Inc. He serves on the board of directors for American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc. He receives income sources or equity of $10,000 or more from American Psychiatric Publishing; Bracket (Clintara); Takeda Pharmaceuticals North America, Inc.; Xhale, Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

Jan Perez, CHCP (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).